Summary of Use during Lactation

No information is available on the clinical use of sorafenib during breastfeeding. Because sorafenib is 99.5% bound to plasma proteins, the amount in milk is likely to be low. However, its half-life is 25 to 48 hours and it might accumulate in the infant. The manufacturer recommends that breastfeeding be discontinued during sorafenib therapy and for 2 weeks after the last dose.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Name

Sorafenib

CAS Registry Number

284461-73-0

Drug Class

• Breast Feeding
• Lactation
• Antineoplastic Agents
• Enzyme Inhibitors
• Protein Kinase Inhibitors
• Signal Transduction Inhibitors
• Tyrosine Kinase Inhibitors